<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01622361</url>
  </required_header>
  <id_info>
    <org_study_id>KBCSG012</org_study_id>
    <nct_id>NCT01622361</nct_id>
  </id_info>
  <brief_title>Premenopausal Patient With Hormone Responsive, HER2 Negative, Lymph Node Positive Breast Cancer</brief_title>
  <acronym>NEST</acronym>
  <official_title>A Phase III, Open-Label, Prospective, Randomized, Multicenter, Neo-adjuvant Study of Chemotherapy Versus Endocrine Therapy in Premenopausal Patient With Hormone Responsive, HER2 Negative, Lymph Node Positive Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Korean Breast Cancer Study Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare neo-adjuvant therapy of cytotoxic chemotherapy versus
      GnRHa with tamoxifen , of response rate(RR) in patients of hormone responsive and HER2
      negative, lymph node positive, primary breast cancer in premenopausal women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Primary objective

           : Response Rate-MRI and/or Caliper

        2. Secondary objectives

             -  Pathologic complete response

             -  Rate of conservation surgery

             -  Ki-67 changes and its relationship to treatment response

             -  Length of time to maximum response within the treatment period

             -  Tolerability of two treatments

             -  Disease-free survival(DFS)

             -  Overall survival
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">February 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pathologic complete response</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">290</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Chemotherapy Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Chemotherapy Adriamycin+Cyclophosphamide&gt;Docetaxel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Endocrine therapy group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endocrine therapy(GnRHa with Tamoxifen) group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adriamycin+Cyclophosphamide&gt;Docetaxel</intervention_name>
    <description>Adriamycin 60mg/m2 + Cyclophosphamide 600mg/m2
Route: by slow intravenous bolus
Schedule: every 3weeks for 4 cycle
Docetaxel 75mg/m2
Route: intravenous as per local practice
Schedule: every 3weeks for 4 cycle</description>
    <arm_group_label>Chemotherapy Group</arm_group_label>
    <other_name>Chemotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GnRHa with Tamoxifen</intervention_name>
    <description>Goserelin(GnRHa) 3.6mg
Route: subcutaneously under the abdominal skin
Schedule: every 4weeks for 6cycles (period of 34 days between 2 administrations must not be exceeded)
Tamoxifen 20mg/day
Route: Oral
Schedule: everyday</description>
    <arm_group_label>Endocrine therapy group</arm_group_label>
    <other_name>Endocrine Therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically proven primary invasive breast cancer which is thought to be suitable
             for neo-adjuvant treatment

          2. Pathologically proven lymph node positive tumor(FNAB or Core biopsy)

          3. Tumor must be ER positive(eligible patients include Allred score 5 and more, Modified
             Allred 4 and more) and HER-2 negative(IHC score is 0-1+; If IHC score is 2+, the
             result of FISH or SISH is negative)

          4. Premenopausal women

             Premenopausal status as defined by :

               -  Last menses within 6 month of randomization or

               -  For patients who have had a unilateral oophorectomy, E2 ≥ 20PG/mL and FSH &lt;
                  30mIU/Ml within 4 weeks of randomization

          5. over 20 years old

          6. Pre-treatment haematology and biochemistry values within acceptable limits :

               -  ANC ≥ 1.5 × 109/l

               -  Hb &gt; 9g/dl

               -  Platelets ≥ 100 × 109/l

               -  AST/ALT ≤ 1.5 × ULN(Upper Limit of Normal)

               -  ALP ≤ 1.5 × ULN

               -  Serum bilirubin ≤ 1.5 × ULN

               -  Serum creatinine ≤ 1.5 × ULN

          7. ECOG PS of 0 or 1

          8. No concomitant medical, psychiatric or geographic problems that might prevent
             completion of treatment or follow-up

          9. Before any study-specific procedures, the appropriate written informed consent must be
             obtained

        Exclusion Criteria:

          1. Inflammatory breast cancer

          2. Inoperable disease that is judged very unlikely to be rendered operable by
             neo-adjuvant treatment

          3. Known severe hypersensitivity to GnRHa treatment

          4. Bilateral invasive breast cancer

          5. Other serious illness or medical condition:

               -  congestive heart failure or unstable angina pectoris, previous history of
                  myocardial infarction within 1 year from study entry, uncontrolled hypertension
                  or high-risk uncontrolled arrhythmias

               -  history of significant neurologic or psychiatric disorders including psychotic
                  disorders, dementia or seizures that would prohibit the understanding and giving
                  of informed consent

               -  active uncontrolled infection

          6. HRT within 4 weeks of starting treatment

          7. Definite contra-indications for the use of corticosteroids.

          8. Last 10 years with a history of other malignant tumor (except in the case of basal
             cell carcinoma or cervical carcinoma in situ, and where treatment consisted solely of
             resection)

          9. Systemic metastatic (Tests for the diagnosis of systemic metastatic comply with the
             guideline in each institution)

         10. Pregnant or breastfeeding women

         11. Chronic oral treatment with corticosteroids unless initiated &gt; 6 months prior to study
             entry and at low dose (≤ 20 mg methylprednisolone or equivalent).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ahn Sei Hyun, MD.PhD</last_name>
    <phone>82-2-3010-3490</phone>
    <email>ahnsh@amc.seoul.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Songpa-gu</state>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahn Sei Hyun, M.D.</last_name>
      <phone>82-2-3010-3490</phone>
      <email>ahnsh@amc.seoul.kr</email>
    </contact>
    <investigator>
      <last_name>A. S. Hyun, MD.PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2012</study_first_submitted>
  <study_first_submitted_qc>June 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2012</study_first_posted>
  <last_update_submitted>September 26, 2013</last_update_submitted>
  <last_update_submitted_qc>September 26, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Sei-Hyun Ahn</investigator_full_name>
    <investigator_title>M.D., Ph.D.</investigator_title>
  </responsible_party>
  <keyword>Neoadjuvant</keyword>
  <keyword>endocrine therapy</keyword>
  <keyword>premenopausal</keyword>
  <keyword>hormone responsive</keyword>
  <keyword>HER2 negative</keyword>
  <keyword>lymph node positive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

